Loading stock data…
Indaptus Therapeutics (INDP)
$3.08-0.33 (-9.68%)
Market OpenUpdated 3:11 PM EDT
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Indaptus Therapeutics, Inc. in the Healthcare sector is trading at $3.08 with a market capitalization of $396M. The stock is currently near its 52-week low of $0.92, remaining 22.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.16M↑ | -$8.16M↓ | -$2.65M↑ | -$4.46M↑ | -$4.57M |
| Net Income | -$2.54M↑ | -$8.11M↓ | -$2.98M↑ | -$5.23M↓ | -$4.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$396.35M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1511.20%
Volume
Today's trading volume
209,890